good luck convincing communists to give back what is not theirs 😂
but really, lemmy is not good for this. your comment exists in multiple physical copies on every instance from which someone interacted with the thread. it is prime example of once it is out there, it is out there forever…
unfortunately, trump is not a cause of the problem - he is just a symptom of bigger underlying problem in society, which is manifesting itself all over the world. so your passport is really not a solution, at least not long term one.
Because lot of people got rich by being selfish assholes, so you can’t really expect them to change now. But some people can afford it and are.
Just saw this graph in neighbouring comment.
https://climatechangetracker.org/igcc/yearly-total-human-induced-net-CO2-emissions
It is not going down, but at least it stopped going up in last 10 years. So something is happening.
It will take time. I drive 10 yo ICE car and I can’t afford new ev car now, but hopefully before my current car will die in 5+ years, second hand ev market will exist.
That last graph is actually slightly optimistic…
https://climatechangetracker.org/igcc/yearly-total-human-induced-net-CO2-emissions
Fuel density doesn’t matter, what matters is how far you can drive on a charge.
Charge time doesn’t matter if you can swap a battery in 3 minutes instead of waiting to charge.
Also you’re ignoring that fossil fuels are also dug out of the ground
i am not, i am not defending fossil fuel, i am just pointing out that the ev concept has problems that are not widely talked about.
just because some other strategy has problems doesn’t mean your strategy is problem free.
Are those two things actually important?
yes, they are. they make difference between actually usable technology and engineer’s dream.
Electric motors are a lot more efficient, and battery technology is quickly approaching the place where you can get the same range with an electric motor as with an ICE.
i doubt we even have enough rare metals for 8 or 16 billion batteries. most of them are being mined in politically unstable or to western civilization unfriendly countries, with terrible effect on the environment.
efficiency matters, it is not a question of how good single battery is.
As for refuel rate, I spend no time waiting for my car to charge because it charges at home while I’m sleeping, so the refuel rate doesn’t matter.
oh good. YOU have it solved, so the rest of the world does not matter, i assume…? fuck all these people, right?
the truth must be told: Firefox is not as optimized as Chrome
what are you talking about? my desktop pc is amd fx4300. definition of old and subpar - https://i.imgur.com/WBm5Ub1.png - and i have 313 open tabs right now.
granted, that is slightly more affected by memory, before i updated from 8 to 32 gb recently, it was admittedly slightly more sluggish.
but at the same time normal people don’t really have 300 open tabs at once and also you have to ask what is the threshold where you are willing to sacrifice your privacy for slight speed increase.
do you have some numbers to support that speed difference, or is it just your feeling, or anecdote that is being passed around and everyone repeats it and everyone believes it, because everyone says so?
what i don’t get is all the people complaining about google and at the same time using their browser…
i believe that trying to steer masses away from chrome would be more useful in the long run than trying to make it work
If your keyboard was actually working, you pressed a key. If it was not working, you went to get new keyboard. What is “not thought through” about that?
unfortunately czechs dropped from 3 to just 1 seat 😒
so, all hopes on her. but definitely no pressure 😂
there is also plastic age…
https://www.theguardian.com/environment/2019/sep/04/plastic-pollution-fossil-record
After bronze and iron, welcome to the plastic age, say scientists
Plastic pollution is being deposited into the fossil record, research has found, with contamination increasing exponentially since 1945.
Scientists suggest the plastic layers could be used to mark the start of the Anthropocene, the proposed geological epoch in which human activities have come to dominate the planet. They say after the bronze and iron ages, the current period may become known as the plastic age.
The study, the first detailed analysis of the rise in plastic pollution in sediments, examined annual layers off the coast of California back to 1834. They discovered the plastic in the layers mirrors precisely the exponential rise in plastic production over the past 70 years.
Sure, the FDA could go against the recommendation
narrator: it did not, in fact, go against the recommendation…
F.D.A. Panel Rejects MDMA-Aided Therapy for PTSD
An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
By Andrew Jacobs June 4, 2024
An independent advisory panel of the Food and Drug Administration rejected the use of MDMA-assisted therapy for post-traumatic stress disorder on Tuesday, highlighting the unparalleled regulatory challenges of a novel therapy using the drug commonly known as Ecstasy.
Before the vote, members of the panel raised concerns about the designs of the two studies submitted by the drug’s sponsor, Lykos Therapeutics. Many questions focused on the fact that study participants were by and large able to correctly guess whether they had been given MDMA, also known by the names of Ecstasy or molly.
The panel voted 9-2 on whether the MDMA-assisted therapy was effective, and voted 10-1 on whether the proposed treatment’s benefits outweighed its risks.
Other panelists expressed concerns over the drug’s potential cardiovascular effects, and possible bias among the therapists and facilitators who guided the sessions and may have positively influenced patient outcomes. A case of misconduct involving a patient and therapist in the study also weighed on some panelists’ minds.
Many of the committee members said they were especially worried about the failure of Lykos to collect detailed data from participants on the potential for abuse of a drug that generates feelings of bliss and well-being.
“I absolutely agree that we need new and better treatments for PTSD,” said Paul Holtzheimer, deputy director for research at the National Center for PTSD, a panelist who voted no on the question of whether the benefits of MDMA-therapy outweighed the risks.
“However, I also note that premature introduction of a treatment can actually stifle development, stifle implementation and lead to premature adoption of treatments that are either not completely known to be safe, not fully effective or not being used at their optimal efficacy,” he added.
While the vote is not binding on the F.D.A., the agency often follows the recommendations of its advisory panels. A final decision by the agency is expected in mid-August.
MDMA, or methylenedioxymethamphetamine, also sometimes referred to as midomafetamine is a synthetic psychoactive drug that fosters self-awareness, feelings of empathy and social connectedness.
The illegal drug is listed as a Schedule I substance, defined as having no accepted medical use and a high potential for abuse. Should it win F.D.A. approval, federal health authorities and Justice Department officials would have to follow certain steps to downgrade the drug’s listing, much like the process now underway with cannabis.
The D.E.A. might also set production quotas for the drug ingredients, as it does with stimulant medications used to treat ADHD.
With the panel’s focus on such topics as “euphoria,” “suicidal ideation” and “expectation bias,” the daylong session on Tuesday demonstrated the nuances and complexities facing regulators as they grapple with the terra incognita of a therapy that only recently entered mainstream psychiatry after the nation’s decades-long war on drugs.
An added wrinkle: the F.D.A. is a regulator of medications. It does not regulate psychotherapy and has not evaluated drugs whose efficacy is tied to talk therapy.
If approved, MDMA-assisted therapy would be the first new treatment for PTSD in nearly 25 years. The condition, which affects some 13 million Americans, has been implicated in the outsized suicide rates among military veterans, whose suffering has galvanized lawmakers from both parties and prompted a sea change in public attitudes about therapies reliant on psychedelic compounds.
According to the studies submitted by Lykos, patients who received MDMA plus psychotherapy reported significant improvements in their mental health. The most recent drug trial found that more than 86 percent of those who took MDMA achieved a measurable reduction in severity of their PTSD symptoms.
About 71 percent of participants improved enough that they no longer met the criteria for a diagnosis. Of those who took the placebo, 69 percent improved and nearly 48 percent no longer qualified for a PTSD diagnosis, according to the submitted data.
The questions, concerns and evident skepticism voiced by the 10-member panel echoed those raised by agency staff members, who last week issued a briefing document aimed at helping the panel evaluate the efficacy and potential adverse health effects of MDMA therapy.
In her opening remarks, Dr. Tiffany Farchione, director of the F.D.A.’s division of psychiatry, noted the regulatory challenges posed by MDMA, saying “we’ve been learning as we go along.” But in her testimony and in staff documents, she and other agency officials repeatedly noted that the overall study results were significant and lasting.
“Although the application presents a number of complex review issues, it does include two positive studies in which participants in the midomafetamine arm experienced statistically significant and clinically meaningful improvement in their PTSD symptoms,” she said. “And that improvement appears to be durable for at least several months after the end of the acute treatment period.”
Much of the criticism about Lykos’s study designs focused on so-called functional unblinding, a problem that affects many studies involving psychoactive compounds. Although the roughly 400 patients who took part in the studies were not told whether they had received MDMA or a placebo, to reduce the odds of bias in the results, the vast majority were acutely aware of any altered state of mind, leading them to correctly guess which study arm they were enrolled in.
The F.D.A., which worked with Lykos to design the trials, has acknowledged shortcomings in the study designs and recently issued new guidance to address the issues facing psychedelic researchers.
A number of other critical voices emerged in recent months. They include the Institute for Clinical and Economic Review, a nonprofit that examines the costs and effectiveness of medications, which issued a report calling the effects of the treatment “inconclusive” and questioning Lykos’s study results.
Other organizations, like the American Psychiatric Association, have not opposed approval outright, but have called on the F.D.A. to mitigate any potential negative consequences by crafting rigorous regulations, strict prescribing and dispensing controls, and close monitoring of patients.
The F.D.A. staff analysis recommended that approval should be contingent on restricted health care settings, monitoring of patients and diligent reporting of adverse events.
Just before they voted on Tuesday, the advisory panel heard from more than 30 speakers who offered starkly divergent views on the application.
Several critics focused on Rick Doblin, a veteran psychedelics advocate who in 1986 founded the Multidisciplinary Association for Psychedelic Studies, the nonprofit organization that filed the original application for MDMA-assisted therapy with the F.DA. The organization later created a for-profit entity that earlier this year became Lykos.
Brian Pace, a lecturer at Ohio State University, described the company applying for approval as a “therapy cult” and criticized Mr. Doblin’s public comments highlighting his zeal for psychedelics, including a belief that legalizing and regulating them would bring about world peace.
But the majority of those who spoke in favor of the application offered deeply personal accounts of how MDMA-therapy had largely quieted the symptoms of their PTSD.
Among them was Cristina Pearse, who said she suffered from PTSD after being sexually assaulted when she was 9. Over the years, she said she had been prescribed a litany of psychiatric medications and at one point she attempted suicide.
MDMA therapy, she said, changed her life. “What used to feel like a tsunami of overwhelming panic was now merely a puddle at my feet,” said Ms. Pearse, who started an organization that helps women recovering from trauma.
She ended her testimony by urging the F.D.A. to approve the application.
“How many more people need to die before we approve an effective therapy?” she asked. “As you weigh the risk, please keep in mind that this therapy can save many lives. I lost most of my life to this disease. I’m grateful to reclaim it now. But I wish this was an approved medication decades ago.”
ok, that’s fair, never thought of that…
Removed by mod
Removed by mod
private planes are much more dangerous, being almost as dangerous per mile as a regular car
that is because they are operated by semi-competent people who often have less practice then they have in car.
imagine how competent driver you are when you have your fresh license. it is the same with piloting license. and now imagine you are a hobby pilot and can afford to spend in the cockpit 3 hours per month. your skill is not really going to get significantly better. you are probably flying airplane that is at the end of its life, because that is only one you can afford, and there may be no one keeping an eye on you telling you “this is not how we do it, it is risky, dangerous, and you will get someone killed”.
Removed by mod
Removed by mod
Removed by mod
in my experience - not very well. i have received answer to deleted comment more than once.